


SUPPLEMENTARY INFORMATION

HUMAN LINCRNA-P21 SEQUENCE


> lincRNA-p21

TGGCAGTCTGACCCACACTCCCCACGCC
GGACCAAGTCGCCTGAGCCCCATAGCCACA
CTCTGCCGGCTTGCCCAGGGCTTGCCCTGGTGC
ATCATCTCCAGCTTGCCAGGGTGCAGAAGTG
AACCAACCACTCAGCGCTGGAAAAACAGCTAA
TTATATCTCAAAGACCCAGGGCAAGAACCTGTG
GACAACCTCAGCTGGCTGGCCTGTCCCACTCGC
TTTCCATTCCCCCACCCTGAGACAGGATGCCA
CTGTGTAGCCCAGTGTAGTGAACACTTGGAA
AAAATAAAGATGGTGAATGAGACATTCCGTCTC
CAGTTCTAACATCAGAAGTGAGCACCTGTG
CACCAAGCAACATATTGGAGGCCAGCTGCCTACAC
CAATCAGAAACAGGGACCACAAAGTCTGCAGGG
GTGAGATAGGCCTTTCAGTGTCTACGATTTCATC
ATGGACATTACTGTCGATTCTCTTCTGCCCTG
TATGTGCGGGTCTATGCCATCTGCCATCTCCGG
CTCCTGTGTTATGAAGACAGTCTCATGCAGCCC
GACCAATCTAAATTGACTAGGTAAACTGAGGCT
GGCCTGAACCAGTCCCTCCTGCCCTATCTCTG
AGAGCTGGTAACAGCTTCTGGAGCCTACCCA
GCTTCGCTTACCAACCCCCAGCCAATCCTGTGAC
TCCTCTCATAGCGAGAGCATTGACACTTATGTC
TGAGTGTGAAAAAAAAAAAAAAATCACATAGTA
CTTCCTACTAGAACCTTGCCCCGGTCAACTGAAG
TGTGTGTGTTGCTTACCAAGTCTGCAGGTTGCTT
AAGTTTGTATTAGAGACCAGGCTTGCTCTG
TTGCCTAACGCAACTTGAAACTCTGGGCTCAA
CAGTTCTCCTGCTCCATCTTAGAGCAGCTGG
GACTCTAGGCATGCTCACTACAGCTGACTGAAG
CTTGAATGAATGAATGAATGAATGAATGAGTTAC
TACCTCTGAGGGACCCCTCATGCCCTCTCAA
CTCTGTACTTAATTAGTTGCTTAGAGGTGTC
ATGCCCTCAGTTCCCCATCTGTAATAGTAAACGA
GTTCACAGGCGTGGTCTGTGCTTGGAGCAAGAA
CAAAACCATCTGGCTATACTCTAGGGACTC
TACAGAGCCCCATCCCTTGGCTATCAGACTGTTG
AGATAAAGGTTCCCCCAGGAATCGGAATCCCCCTC
CGACAGGAGTCTCATGCTCAGAGAAGAAAAAAA
GCTGAAGCCTGCTGACAGCCAGAGAGGGTACTT
GTCTGTCAAGGAAAAAATTCTACACAGGACAGAC
TGGAGCCCAGACTGGTCTGGGTCAGTGCACACAC
GGCACAGCACACGGTGGACAACCTGGCTGTGC
ATCTCTCTCAAACCTTGTACCCCTCTCACTG
TGGCCACAGCGAAGCGAATACATCTCTGCTTT
TCACTACGTAGCTCCATCATTGCCCTGGGGGGGG
GTAGCGAGGAAGGTCACTGGGGCCCTGCCTCTG
ATAAGAAGAACGAGCAATTATGATTCCAGGAA
CCGAGGGTGCTCTGCTGTCAGTGTCTCCAGCA
CCCCCGGAGACCCCAAGGGCTGCCGTCAAGGGTG
TTCAATAAACACGTATCGATTGAGCCAACAATGC


CAGAATTGGACCTGCAGAGGAGAAAAATGGACAA
ACAAGACAGT GAGCCTGCAGGTGAGACCAGAA
CTGGAGCCAACAATCTACCTCTCTCTCCAAACCC
TAGCAACGCCAGCAGCTCTGGCGAGGGGCA
CAGTTGCTTCCAGTTGGCAGAACCCAGCACCTGCTGAGCCA
GCTTCCCTTCAGAACCCAGCACCTGCTGAGCCA
CCGACCCACGGACTGTCTCTCTGGAAGGCAG
CCACCGACCCACGGACTGTCTCTCTGGAAGG
CAGTTCACCTCTGGTTCAACACTGCCCTTCC
CCTTCCTTCTTAGCCCTAGGAATCCCTGAAA
GCTTCCTGTGCTTGTGGCTCTGTGACTTCTCAA
CATCTCTTGTGACACACACACACACACACACA
CACACACACCAGCCTGTGCTAAGCAGTTCATC
CTGTACAATGTCTCTGTATAAAAATGATTC
CATTCTGTACCTGCTGAGGCTCCAGCAGCTCT
GCCCTCAGACCTTAAAGCTGAGGCTCAGAAG
CACAGGGAGGCACGGGAACCTGGTCCCAGGCC
CTGGCTTGTGGAGCGAAGGAATCTATTGCTTCG
GCCACTCGGTAGAATCCCTCGGAGATTGATGTG
ATATGCACAGTGACACCCAATCGGGCTTGGAAAA
CTGGGCAACAGTTAACAGGCCACACAAAGGAACTA
ACCACAGCTCCACTGGCAACTGGCTCCTTGGCA
AGTGCCAAAACAAACAGCTGTGGTGAGGCCTT
CCCCGGGCTGCCGGCTTCTGGACACTGGCAGA
GGCGCTCAAGAAGGGAGTACCTGAGTAGGGTG
TTGTTCAGTTGGTAGAACGTTGCTGCACCTCATACCTG
TGAAGGCCAGGGTCTGTCTGCACCTCATACCTG
TGATCCTAGCAGTTGGAAAAGACAGCAAGCAC
CCGGATCAGAAGTCAAGACCACCCCTCCCTTA
TAAAGGGATCTGAGGCAGCCTGGACATCTGAA
TGACAAATGAAAAGAGCCGTGAGCTATCTGGTG
TTTCTTCATGGAAGTCCAAGTCTCCCCCTCAT
CCTCCCAGGATTCTCCGAATCTGGCTTGTGCTT
TTGCGATATTAGAATATTCTAGCCAGAGCGCA
GAGTATAAAATACAAGTCAAAGGCAATGAGCATA
TGTTAGATGGATGGAGGAGGGCTAAAAATGCT
GGTGCCTGGGAGGAAAATGGCTCAGCAGTTAA
GAGCACCGGCTGCTTACAGAGGACCTGCCTT
CAGTTACAGCAACCGCATGACGGCAACTCTGG
TTCCAGGAATCCAATGCCCTCTGACCTCTA
TAGGCACCCGGCAAGCACACAGTGCACAGACAA
TCATACACACGTGT.




Supplementary Figure S1: lncRNAs level in normal liver tissues and human hepatocellular carcinoma (HCC).
** $p < 0.01$ vs. normal. $N = 10$.




Supplementary Figure S2: Lentivirus-mediated lincRNA-p21 knockdown in Huh7 and Bel-7402 cells. Huh7 **A.** and Bel-7402 **B.** cells were infected with lentivirus carrying sh-Ctrl or sh-lincRNA-p21 for 48 hours. The level of lincRNA-p21 was analyzed with q-PCR. ** $p < 0.01$ vs. sh-Ctrl.




Supplementary Figure S3: LincRNA-p21 knockdown promotes cell proliferation and colony formation in HepG2 cells. **A.** Representative image showing lincRNA-p21 knockdown promotes HepG2 cell proliferation. The photographs were captured 48 hours post infection of lentivirus. **B.** LincRNA-p21 knockdown promotes HepG2 cell proliferation. ** $p < 0.01$ vs sh-Ctrl 0 day; # $p < 0.05$ and ## $p < 0.01$ vs sh-Ctrl of the corresponding time points. **C.** Representative photograph showing lincRNA-p21 knockdown promotes colony formation of HepG2 cells.




Supplementary Figure S4: Sorafenib promotes lincRNA-p21 expression. **A.** HepG2 cells were treated with 20 μ M sorafenib for 48 hours. LincRNA-p21 expression was analyzed with q-PCR. ** $p < 0.01$ vs control (Veh). **B.** Tumor xenograft experiment was performed. The mice were sacrificed four weeks after tumor implantation. Sorafenib (30 mg/kg/d) was administered in 100 μ L by intraperitoneal injection on day three after tumor implantation. LincRNA-p21 expression was analyzed with q-PCR. ** $p < 0.01$ vs control (Veh). $N = 5$ in each groups.




Supplementary Figure S5: Quantitative data related to Figure 6E. ** $p < 0.01$ vs. U6 24 hours.




Supplementary Figure S6: lincRNA-p21 activates PERK (Protein kinase RNA-like endoplasmic reticulum kinase). HepG2 cells were infected with indicated lentivirus for indicated times.



Supplementary Figure S7: Quantitative data related to Figure 6G. ** $p < 0.01$ vs. U6 24 hours.



Supplementary Figure S8: Quantitative data related to Figure 7D–7G. **A.** Quantitative data related to Figure 7D. $n = 5$. **B.** Quantitative data related to Figure 7E. The experiments were repeated for three times. **C.** Quantitative data related to Figure 7F. The experiments were repeated for three times. **D.** Quantitative data related to Figure 7G. The experiments were repeated for three times. ** $p < 0.01$ vs. PBS+sh-Ctrl; ## $p < 0.01$ vs. Sorafenib+sh-Ctrl.



Supplementary Figure S9: LincRNA-p21 regulates oxidative stress. HepG2 cells were infected with indicated lentivirus for 24 hours. **A.** DHE staining was performed to test the total ROS level. Relative total ROS level is shown. **B.** Representative western blot showing lincRNA-p21 increases the level of DUOX1 (dual oxidase 1).

Supplementary Table S1: Primers used for q-PCR

Name	Sense (5'-3')	Antisense (5'-3')
lincRNA-p21	CCTGTCCCCTCGCTTTC	GGAACGGAGACGGAATGTC
IRE1	CAGTGGCCTTGGTG GGTGTG	GTCTGGGTCTCGCTGCT CTCCT
CHOP	CAACACTCTTGACCC TGCTTCTCT	GTTCCTGGTTCTCCCTT GGTCTT
GRP78	TTCGGCACCTCGGTAACCT	GGACTGCGTGATCTCCCTCT
MDM2	TCGTCGGGTGAGGGTACTG	AACCACTTCTTGAACCAGGT
BAX	CATATAACCCCCGTCAACGCAG	GCAGCCGCCACAAACATAC
PUMA	GCCAGATTGTGAGACAAGAGG	CAGGCACCTAATTGGGCTC
NOXA	CCAAGCCGTGACCAAGGAC	CGCCACATTGTGTAGCACCT
β-actin	GACCTGACTGACTACCTCATGAAGAT	GTCACACTTCATGATGGAGTTGAAGG

Supplementary Table S2: sh RNA sequences targeting human lincRNA-p21.

Sh-RNA	Sequence (5'-3')
lincRNA-p21-1#	GGAGGACACAGGGAGAGGA
lincRNA-p21-2#	GCCACCCACTCACCAGTGG
lincRNA-p21-3#	GCATTGTTGCATCATCATG
lincRNA-p21-4#	CTGCAAGGCCGCATGATGA